Apellis Pharmaceuticals Business Summary

Apellis Pharmaceuticals, Inc. (APLS) is a commercial-stage biopharmaceutical leader specializing in the discovery and development of C3-targeted complement inhibitors. The company generates revenue primarily through net product sales of its two flagship therapies: SYFOVRE (pegcetacoplan injection), the first-ever FDA-approved treatment for geographic atrophy (GA), and EMPAVELI (pegcetacoplan), utilized for paroxysmal nocturnal hemoglobinuria (PNH) and recently expanded into C3 glomerulopathy (C3G) and primary IC-MPGN. Beyond direct sales, Apellis captures value through strategic licensing and milestone payments, most notably via its restructured collaboration with Swedish Orphan Biovitrum (Sobi) for ex-U.S. commercialization. The company operates across three primary segments: ophthalmology, hematology, and nephrology. Apellis maintains a dominant market position in the GA space with a roughly 60% market share, competing directly against Astellas Pharma (Izervay), Roche (Vabysmo), and Regeneron (Eylea). Apellis was co-founded by Dr. Cedric Francois and Dr. Pascal Deschatelets, both of whom possess deep expertise in immunology and previously collaborated on the development of Potentia Pharmaceuticals. Dr. Francois serves as the President and Chief Executive Officer, bringing a background as a physician-scientist and serial entrepreneur, while Dr. Deschatelets serves as the Chief Scientific Officer. The executive leadership team is further bolstered by Timothy Sullivan (Chief Financial Officer), Nur Nicholson (Chief Technical Operations Officer), and Dr. Caroline Baumal (Chief Medical Officer). The company’s governance is overseen by a board of directors chaired by Dr. Gerald Chan, co-founder of Morningside Group. Apellis is backed by a robust roster of institutional investors, including BlackRock, Vanguard Group, State Street Corporation, and Wellington Management, reflecting strong capital market confidence in its C3-inhibition platform.